BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32431130)

  • 1. [NEOADJUVANT TREATMENT OF LOCALLY ADVANCED ESTROGEN/PROGESTERONE POSITIVE, HER2NEU NEGATIVE BREAST CANCER].
    Friedman NS; Shaham L; Sharon N; Barlev C
    Harefuah; 2020 May; 159(5):370-375. PubMed ID: 32431130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of breast cancer in countries with limited resources.
    Carlson RW; Anderson BO; Chopra R; Eniu AE; Jakesz R; Love RR; Masetti R; Schwartsmann G;
    Breast J; 2003; 9 Suppl 2():S67-74. PubMed ID: 12713499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
    Madigan LI; Dinh P; Graham JD
    Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neoadjuvant endocrine therapy for locally advanced breast cancer].
    Viola G; Sergi D; Conti F; Lopez M
    Clin Ter; 2007; 158(5):441-52. PubMed ID: 18062352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neo-adjuvant hormonal therapy.
    Valenzuela M; Julian TB
    Breast J; 2008; 14(3):279-83. PubMed ID: 18373643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant and Adjuvant Therapies for Breast Cancer.
    Apuri S
    South Med J; 2017 Oct; 110(10):638-642. PubMed ID: 28973704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
    Dixon JM; Jackson J; Renshaw L; Miller WR
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):295-9. PubMed ID: 14623524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
    Hoff PM; Valero V; Buzdar AU; Singletary SE; Theriault RL; Booser D; Asmar L; Frye D; McNeese MD; Hortobagyi GN
    Cancer; 2000 May; 88(9):2054-60. PubMed ID: 10813717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.
    Dixon JM; Anderson TJ; Miller WR
    Eur J Cancer; 2002 Nov; 38(17):2214-21. PubMed ID: 12441257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoadjuvant endocrine therapy for breast cancer: an overview].
    Domont J; Namer M; Khayat D; Spano JP
    Bull Cancer; 2004 Jan; 91(1):55-62. PubMed ID: 14975805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.